Marinus Pharmaceuticals (MRNS)

Data from SEC filings
Employee count
ESG framework mentions
In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
ESG term mentions
In last year of SEC filings
AirEcologicalEnvironmentEnvironmentalExtreme WeatherIntensityLife CycleMaterialsNatural ResourcesNatureOffsetPackagePackagingPandemicRaw MaterialsRegenerativeWaterAccessAfrican AmericanAsianBenefitsBlackCalifornia Consumer Privacy ActCharitableCollective BargainingCommunityCultureCustomerCyberCybersecurityData PrivacyData SecurityDeathDemographicDemographicsDisabilityDiversityDrug PricingEmployeeEmployee EngagementEngagementEthnicityGenderGeneral Data Protection RegulationHealth and SafetyHealth CareHealthcareHireHiringHispanicHuman CapitalHuman ResourcesIncidentInjuriesInjuryLabor StandardsLGBTQOpioidPerquisitesPrivacyProduct QualityProduct SafetyRecallRecruitmentReimbursementRetentionRetirementSafetySatisfactionSkillSkilledSkillsSocialSocietyStakeholderSupplierSupply ChainTalentTrainingUnionVolunteerWomenWorkforceAction PlanAssessmentAssuranceAttorney GeneralAttorneys GeneralAuditBoard OversightBonusBriberyChronicClass Action LawsuitClassifiedClassified BoardClawbackCommitmentConflict of InterestCorporate GovernanceCorporate Social ResponsibilityCorruptionDepartment ofESGEthicsExecutive CompensationExpertFraudGoalsGovernanceHedgingIncentiveIndependenceIndependentInnovationInnovativeInvestigationLawsuitLead Independent DirectorLeadershipLitigationLong-termMajorityMissionOverseeOversightPerquisitePlaintiffPledgingPoison PillProcurementPurposeR&DRecoupReputationReputationalResearch and DevelopmentResponsibilityResponsibleSelf-evaluationSpecial MeetingStockholder EngagementStockholder OutreachStrategySustainabilitySustainableTargetsTaxTenureTransparencyVoting Rights
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On May 26, 2021, Marinus Pharmaceuticals, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 36,633,490 shares of common stock outstanding and entitled to vote at the Annual Meeting, 26,891,520 shares, or 73.4% were present, either by remote communication or represented by proxy, constituting a quorum. The following provides a summary of the votes cast for the proposals on which the Company’s stockholders voted at the Annual Meeting:

Proposal 1: Election of three Class I directors to the Company’s Board of Directors (our “Board”), each to serve until the Company’s 2024 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified.

The Company’s stockholders elected the following individuals to serve as Class I directors to serve until the Company’s 2024 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified, and the results of the vote were as follows:

Director NomineeVotes ForWithheldBroker Non-Votes
Charles Austin22,978,483379,9053,533,132
Michael R. Dougherty23,014,914343,4743,533,132
Elan Ezickson18,258,8105,099,5783.533,132

Proposal 2: Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021.

The Company’s stockholders approved Proposal 2. The results of the vote were as follows:

ForAgainstAbstainBroker Non-Votes

Proposal 3: Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement for the Annual Meeting.

The Company’s stockholders approved Proposal 3. The results of the vote were as follows:

ForAgainstAbstainBroker Non-Votes